bioAffinity Technologies, Inc. ((BIAF)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
bioAffinity Technologies, Inc. is conducting a study titled ‘Collection of Sputum and Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphyrin (TCPP) for Detection of Lung Cancer.’ The study aims to compare assay results to current lung cancer detection standards and optimize sputum collection methods. This research is significant as it could enhance early lung cancer detection and improve patient outcomes.
The intervention involves analyzing sputum samples using the CyPath® Lung assay. The study evaluates three sputum collection methods to determine the most effective approach for sample analysis, potentially leading to better diagnostic accuracy.
This observational study follows a cohort model, focusing on healthy, high-risk, and cancer patient groups. The primary purpose is to refine the assay for clinical trials and eventual commercialization, without any masking or intervention allocation.
The study began on March 1, 2018, with the latest update submitted on March 26, 2025. These dates indicate the study’s ongoing nature and the continuous effort to refine the assay for better clinical application.
For investors, this study could influence bioAffinity Technologies’ stock performance positively, as successful outcomes may lead to a competitive edge in the lung cancer diagnostics market. The ongoing research and potential commercialization of the assay could attract investor interest and enhance market positioning.
The study is currently recruiting, with further details available on the ClinicalTrials portal.